Cover Image
市場調查報告書

過敏性鼻炎:開發平台分析

Allergic Rhinitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232791
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
過敏性鼻炎:開發平台分析 Allergic Rhinitis - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 135 Pages
簡介

所謂過敏性鼻炎是免疫系統鼻子吸入的物質過度反應時所發生的過敏反應。

本報告提供過敏性鼻炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞及發表的企業和研究機關開發中的治療藥、治療藥評估、後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

過敏性鼻炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

過敏性鼻炎:企業開發中的治療藥

過敏性鼻炎:大學/機關研究中的治療藥

過敏性鼻炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

過敏性鼻炎:企業開發中的產品

過敏性鼻炎:大學/機關研究中的產品

過敏性鼻炎的治療藥的開發企業

  • 3M Drug Delivery Systems
  • Accolade Pharmaceuticals, LLC
  • Adamis Pharmaceuticals Corporation
  • AFFiRiS AG
  • ALK-Abello A/S
  • Ampio Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • ASIT biotech s.a.
  • Axikin Pharmaceuticals, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Chrysalis BioTherapeutics, Inc.
  • ELORAC, Inc.
  • Faes Farma, SA
  • Fountain Biopharma Inc.
  • GenMont Biotech Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • HAL Allergy BV
  • Hanmi Pharmaceuticals, Co. Ltd.
  • 久光製藥
  • J Uriach Y Compania, S.A.
  • Johnson & Johnson
  • Laboratorios LETI S.L.
  • Ligand Pharmaceuticals, Inc.
  • Marinomed Biotechnologie GmbH
  • Merck & Co., Inc.
  • Panmira Pharmaceuticals, LLC.
  • Pfizer Inc.
  • Protectimmun GmbH
  • Regeneron Pharmaceuticals, Inc.
  • RODES Inc.
  • Roxall Medizin GmbH
  • Sanofi
  • 鹽野義製藥
  • Stallergenes SAS
  • 大鵬藥品工業
  • VentiRx Pharmaceuticals, Inc.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

過敏性鼻炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

過敏性鼻炎:最近的開發平台趨勢

過敏性鼻炎:暫停中的計劃

過敏性鼻炎:開發中止的產品

過敏性鼻炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9757IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides an overview of the Allergic Rhinitis (Respiratory) pipeline landscape.

Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy runny nose, sneezing, swollen eyelids, itchy mouth, throat, ears.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Allergic Rhinitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Allergic Rhinitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Rhinitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Allergic Rhinitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 8, 16, 4, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules, respectively.

Allergic Rhinitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Rhinitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Allergic Rhinitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Allergic Rhinitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Allergic Rhinitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Rhinitis (Respiratory)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Allergic Rhinitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Allergic Rhinitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Allergic Rhinitis - Overview
    • Allergic Rhinitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Allergic Rhinitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Allergic Rhinitis - Companies Involved in Therapeutics Development
    • Accolade Pharmaceuticals LLC
    • AFFiRiS AG
    • ALK-Abello A/S
    • AlleCures Inc
    • Allergy Therapeutics Plc
    • ASIT Biotech SA
    • Axikin Pharmaceuticals Inc
    • Chong Kun Dang Pharmaceutical Corp
    • Chrysalis BioTherapeutics Inc
    • Fountain Biopharma Inc
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd
    • HAL Allergy BV
    • Hisamitsu Pharmaceutical Co Inc
    • Intrommune Therapeutics
    • J Uriach Y Compania SA
    • Laboratorios LETI SL
    • Paradigm Biopharmaceuticals Ltd
    • Sanofi
    • Stallergenes Greer plc
    • Sun Pharma Advanced Research Company Ltd
    • Taiho Pharmaceutical Co Ltd
    • Therabron Therapeutics Inc
    • Xencor Inc
  • Allergic Rhinitis - Drug Profiles
    • (fexofenadine hydrochloride + phenylephrine hydrochloride) - Drug Profile
    • (mometasone furoate + olopatadine hydrochloride) - Drug Profile
    • 854-A - Drug Profile
    • Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile
    • Allergen for Allergic Rhinitis - Drug Profile
    • Allergen for Allergic Rhinitis and Allergic Rhino-Conjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Allergic Asthma - Drug Profile
    • Allergen for Asthma and Perennial Allergic Rhinitis - Drug Profile
    • Allergen for Birch Pollen Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mite Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for House Dust Mites Induced Persistant Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
    • Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile
    • arabinogalactan - Drug Profile
    • B-244 - Drug Profile
    • bepotastine besilate SR - Drug Profile
    • BM-41 - Drug Profile
    • CBP-174 - Drug Profile
    • CG-201 - Drug Profile
    • CPC-888 - Drug Profile
    • emedastine difumarate - Drug Profile
    • FB-825 - Drug Profile
    • gp-ASIT - Drug Profile
    • GSK-2245035 - Drug Profile
    • hdm-ASIT - Drug Profile
    • KR-62980 - Drug Profile
    • Lactococcus lactis G121 - Drug Profile
    • levocabastine hydrochloride + mometasone furoate - Drug Profile
    • mometasone furoate - Drug Profile
    • Monoclonal Antibody for Seasonal Allergic Rhinitis - Drug Profile
    • nasapaque - Drug Profile
    • NVP-1703 - Drug Profile
    • pentosan polysulfate sodium - Drug Profile
    • Pollinex Quattro Tree - Drug Profile
    • rag-ASIT - Drug Profile
    • rupatadine - Drug Profile
    • short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
    • Small Molecule for Allergic Rhinitis - Drug Profile
    • Small Molecule to Antagonize CRTH2 for Inflammation and Respiratory Diseases - Drug Profile
    • Small Molecules for Respiratory Disorders - Drug Profile
    • Small Molecules for Seasonal Allergic Rhinitis - Drug Profile
    • Small Molecules to Antagonize H1 and H3 Receptor for Allergic Rhinitis - Drug Profile
    • Small Molecules to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    • standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    • STG-120 - Drug Profile
    • SUN-0597 - Drug Profile
    • SYM-001 - Drug Profile
    • TAS-205 - Drug Profile
    • TO-206 - Drug Profile
    • Vaccine for Asthma and Allergic Rhinitis - Drug Profile
    • Vaccine to Target IgE for Allergic Rhinitis and Asthma - Drug Profile
    • XmAb-7195 - Drug Profile
    • Zafi-3 - Drug Profile
  • Allergic Rhinitis - Dormant Projects
  • Allergic Rhinitis - Discontinued Products
  • Allergic Rhinitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Allergic Rhinitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Allergic Rhinitis - Pipeline by Accolade Pharmaceuticals LLC, H2 2017
  • Allergic Rhinitis - Pipeline by AFFiRiS AG, H2 2017
  • Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2017
  • Allergic Rhinitis - Pipeline by AlleCures Inc, H2 2017
  • Allergic Rhinitis - Pipeline by Allergy Therapeutics Plc, H2 2017
  • Allergic Rhinitis - Pipeline by ASIT Biotech SA, H2 2017
  • Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals Inc, H2 2017
  • Allergic Rhinitis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
  • Allergic Rhinitis - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
  • Allergic Rhinitis - Pipeline by Fountain Biopharma Inc, H2 2017
  • Allergic Rhinitis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Allergic Rhinitis - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Allergic Rhinitis - Pipeline by HAL Allergy BV, H2 2017
  • Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
  • Allergic Rhinitis - Pipeline by Intrommune Therapeutics, H2 2017
  • Allergic Rhinitis - Pipeline by J Uriach Y Compania SA, H2 2017
  • Allergic Rhinitis - Pipeline by Laboratorios LETI SL, H2 2017
  • Allergic Rhinitis - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
  • Allergic Rhinitis - Pipeline by Sanofi, H2 2017
  • Allergic Rhinitis - Pipeline by Stallergenes Greer plc, H2 2017
  • Allergic Rhinitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Allergic Rhinitis - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2017
  • Allergic Rhinitis - Pipeline by Therabron Therapeutics Inc, H2 2017
  • Allergic Rhinitis - Pipeline by Xencor Inc, H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Allergic Rhinitis - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Allergic Rhinitis - Discontinued Products, H2 2017
  • Allergic Rhinitis - Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for Allergic Rhinitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top